Krista Louise Manning, | |
450 Sunshine Dr., Big Piney, WY 83113 | |
(847) 707-6727 | |
Not Available |
Full Name | Krista Louise Manning |
---|---|
Gender | Female |
Speciality | Speech-language Pathologist |
Location | 450 Sunshine Dr., Big Piney, Wyoming |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1043629819 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | 14175890 (Wyoming) | Primary |
Mailing Address | Practice Location Address |
---|---|
Krista Louise Manning, Po Box 584, Big Piney, WY 83113 Ph: (847) 707-6727 | Krista Louise Manning, 450 Sunshine Dr., Big Piney, WY 83113 Ph: (847) 707-6727 |
News Archive
Asthma is the commonest chronic disease in children and a major reason for admissions to hospital, yet inadequate asthma control is present in 26% to 45% of children, states a review http://www.cmaj.ca/embargo/cmaj071638.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.
The New York Times reports: "The nation's drive toward computerized medical records is getting a push from big hospitals, which hope not only to improve patient care but to gain an edge on competitors. And an effort to be announced on Monday by a big New York regional hospital group may be the most ambitious effort of this type yet — a sizable investment intended as a linchpin in the group's $400 million commitment to digitize patient records throughout its system, including 13 hospitals."
Flamel Technologies today announced the initiation of a Phase 2a clinical trial of Flamel's Interferon alpha-2b XL (IFN-alpha-2b XL), which is based on Flamel's Medusa® platform for controlled release of biologics. IFN-alpha-2b XL is being developed as a controlled release of unmodified interferon alpha-2b for the treatment of chronic hepatitis C virus (HCV).
Ikaria, Inc. announced that it has enrolled the first patients in its pivotal Phase III trial for LUCASSIN® (terlipressin). The multi-center, randomized, placebo-controlled, double-blind trial is known as the REVERSE Trial.
› Verified 3 days ago